On Friday, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) opened lower -6.07% from the last session, before settling in for the closing price of $2.47. Price fluctuations for ZNTL have ranged from $1.61 to $18.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 44.92% at the time writing. With a float of $53.57 million, this company’s outstanding shares have now reached $71.15 million.
Let’s look at the performance matrix of the company that is accounted for 168 employees. In terms of profitability, gross margin is 97.68%, operating margin of -490.5%, and the pretax margin is -419.76%.
Zentalis Pharmaceuticals Inc (ZNTL) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zentalis Pharmaceuticals Inc is 24.82%, while institutional ownership is 87.48%. The most recent insider transaction that took place on Feb 06 ’25, was worth 45,656. In this transaction Chief Medical Officer of this company bought 20,000 shares at a rate of $2.28, taking the stock ownership to the 36,629 shares. Before that another transaction happened on Feb 11 ’25, when Company’s Former Director proposed sale 687 for $2.00, making the entire transaction worth $1,374.
Zentalis Pharmaceuticals Inc (ZNTL) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.66 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 44.92% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.52% during the next five years compared to -50.05% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Check out the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). In the past quarter, the stock posted a quick ratio of 7.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.08.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.53, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.52 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) saw its 5-day average volume 0.99 million, a negative change from its year-to-date volume of 2.44 million. As of the previous 9 days, the stock’s Stochastic %D was 74.34%. Additionally, its Average True Range was 0.27.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 25.09%, which indicates a significant decrease from 69.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 140.08% in the past 14 days, which was higher than the 108.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.62, while its 200-day Moving Average is $4.49. Nevertheless, the first resistance level for the watch stands at $2.54 in the near term. At $2.77, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.95. If the price goes on to break the first support level at $2.14, it is likely to go to the next support level at $1.96. Assuming the price breaks the second support level, the third support level stands at $1.74.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
There are currently 71,265K shares outstanding in the company with a market cap of 165.34 million. Presently, the company’s annual sales total 0 K according to its annual income of -292,190 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -88,280 K.
